THX Pharma Société Anonyme (FRA:3VG)
Germany · Delayed Price · Currency is EUR 1.695
+0.185 (12.25%)
At close: Nov 27, 2025
THX Pharma Société Anonyme Company Description
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease.
The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025.
The company was founded in 2013 and is headquartered in Lyon, France.
THX Pharma Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Pharmaceutical Preparations |
| Employees | 10 |
| CEO | Mathieu Charvériat |
Contact Details
Address: 60, Avenue Rockefeller Lyon, 69008 France | |
| Phone | 33 1 88 89 70 31 |
| Website | theranexus.com |
Stock Details
| Ticker Symbol | 3VG |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mathieu Charvériat | Chief Executive Officer |
| Christine Placet | Chief Financial Officer |
| Julien Veys | Chief Operating Officer |